Trinity Biotech plc (TRIB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $4.96M
Last updated: Nov 17, 2026 at 11:05 AM ET
Trinity Biotech plc (TRIB) Earnings: Report Dates and Results
Trinity Biotech (TRIB) is expected to report earnings on Dec 22, 2026. In the quarter ended Mar 31, 2026, Trinity Biotech reported EPS of -$28.12. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
TRIB has an expected report date of Dec 22, 2026.
TRIB Earnings Call
The latest TRIB earnings call transcript on file is labeled 2024Q3.
Read the 2024Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, TRIB beat 18, missed 17 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 258.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | -$28.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 30, 2026 | $11.06M |
| Dec 31, 2025 | -$0.90 | -$0.32 | N/A | -181.25% | Miss | N/A | N/A | N/A | Apr 30, 2026 | $11.06M |
| Sep 30, 2025 | -$0.40 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 1 down | Dec 23, 2025 | $14.25M |
| Jun 30, 2025 | -$14.40 | -$17.10 | N/A | +15.79% | Beat | N/A | 1 | 0 up, 0 down | Jul 1, 2025 | $10.98M |
| Mar 31, 2025 | -$1.24 | -$1.50 | N/A | +17.42% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2025 | $7.58M |
| Dec 31, 2024 | -$26.35 | -$9.00 | N/A | -192.75% | Miss | N/A | 1 | 1 up, 0 down | Jan 29, 2025 | $15.86M |
| Sep 30, 2024 | -$12.77 | -$16.20 | N/A | +21.17% | Beat | N/A | 1 | 1 up, 0 down | Nov 15, 2024 | $15.15M |
| Jun 30, 2024 | -$14.00 | -$19.50 | N/A | +28.21% | Beat | N/A | N/A | N/A | Aug 13, 2024 | $15.84M |
| Mar 31, 2024 | -$3.59 | -$3.60 | N/A | +0.41% | Beat | N/A | N/A | N/A | May 22, 2024 | $14.70M |
| Dec 31, 2023 | -$0.18 | -$0.14 | N/A | -25.00% | Miss | N/A | N/A | 0 up, 0 down | Jan 31, 2024 | $14.70M |
| Sep 30, 2023 | -$30.12 | -$13.50 | N/A | -123.11% | Miss | N/A | N/A | 0 up, 0 down | Oct 3, 2023 | $14.68M |
| Jun 30, 2023 | -$24.78 | -$9.00 | N/A | -175.33% | Miss | N/A | 1 | 0 up, 0 down | Jul 5, 2023 | $13.90M |
| Mar 31, 2023 | -$0.06 | -$0.06 | -$0.06 - -$0.06 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Apr 10, 2023 | $14.83M |
| Dec 31, 2022 | -$27.75 | -$9.00 | N/A | -208.33% | Miss | N/A | N/A | 0 up, 0 down | Mar 23, 2023 | $18.04M |
| Sep 30, 2022 | -$7.70 | -$6.00 | N/A | -28.33% | Miss | -182.8% | 1 | 0 up, 0 down | Dec 15, 2022 | $18.04M |
| Jun 30, 2022 | -$0.03 | -$0.03 | N/A | 0.00% | In line | -100.1% | 1 | 0 up, 0 down | Jul 21, 2022 | $18.46M |
| Mar 31, 2022 | -$11.73 | -$6.00 | N/A | -95.50% | Miss | -11830.0% | 1 | 0 up, 0 down | Apr 11, 2022 | $18.78M |
| Dec 31, 2021 | -$0.06 | $0.07 | N/A | -185.71% | Miss | -100.1% | N/A | N/A | Mar 23, 2022 | $19.52M |
| Sep 30, 2021 | $9.30 | $12.00 | N/A | -22.50% | Miss | -82.7% | N/A | 0 up, 0 down | Dec 15, 2021 | $22.00M |
| Jun 30, 2021 | $30.45 | $10.50 | N/A | +190.00% | Beat | N/A | N/A | 0 up, 0 down | Sep 9, 2021 | $25.84M |
| Mar 31, 2021 | $0.10 | $0.07 | $0.07 - $0.07 | +42.86% | Beat | +88.7% | 1 | N/A | May 25, 2021 | $25.59M |
| Dec 31, 2020 | $53.85 | $21.00 | N/A | +156.43% | Beat | +298.9% | 1 | N/A | Mar 25, 2021 | $32.77M |
| Sep 30, 2020 | $53.70 | $15.00 | N/A | +258.00% | Beat | +7060.0% | N/A | N/A | Nov 17, 2020 | $32.01M |
| Jun 30, 2020 | -$5.40 | -$0.02 | N/A | N/A | N/A | -13600.0% | N/A | N/A | Aug 25, 2020 | $16.02M |
| Mar 31, 2020 | $0.05 | $0.03 | N/A | +76.67% | Beat | -92.9% | N/A | N/A | May 27, 2020 | $21.18M |
| Dec 31, 2019 | $13.50 | $9.00 | N/A | +50.00% | Beat | +19185.7% | N/A | N/A | Mar 31, 2020 | $21.32M |
| Sep 30, 2019 | $0.75 | $9.00 | N/A | -91.67% | Miss | -61.5% | 1 | N/A | Oct 16, 2019 | $24.59M |
| Jun 30, 2019 | $0.04 | $0.07 | N/A | -42.86% | Miss | -99.1% | N/A | N/A | Aug 20, 2019 | $22.50M |
| Mar 31, 2019 | $0.75 | $10.50 | N/A | -92.86% | Miss | -85.3% | 1 | N/A | May 7, 2019 | $22.03M |
| Dec 31, 2018 | $0.07 | $0.04 | $0.04 - $0.04 | +75.00% | Beat | -12.5% | 1 | N/A | Mar 7, 2019 | $24.52M |
| Sep 30, 2018 | $1.95 | $1.80 | N/A | +8.33% | Beat | -80.2% | 1 | N/A | Oct 23, 2018 | $23.71M |
| Jun 30, 2018 | $4.35 | $9.00 | N/A | -51.67% | Miss | -6.5% | 1 | N/A | Jul 19, 2018 | $25.00M |
| Mar 31, 2018 | $5.10 | $7.50 | $1.50 - $7.51 | -32.00% | Miss | +332.2% | 2 | N/A | Apr 20, 2018 | $23.80M |
| Dec 31, 2017 | $0.08 | $0.07 | $0.07 - $0.07 | +14.29% | Beat | -63.6% | 1 | N/A | Mar 7, 2018 | $24.55M |
| Sep 30, 2017 | $9.85 | $8.50 | N/A | +15.88% | Beat | -27.0% | 2 | N/A | Oct 26, 2017 | $25.60M |
| Jun 30, 2017 | $4.65 | $7.50 | $6.01 - $12.01 | -38.00% | Miss | -43.6% | 2 | N/A | Jul 20, 2017 | $25.45M |
| Mar 31, 2017 | $1.18 | $0.90 | N/A | +31.11% | Beat | -72.9% | 2 | N/A | Apr 27, 2017 | $23.54M |
| Dec 31, 2016 | $0.22 | -$0.80 | N/A | +127.50% | Beat | +100.0% | N/A | N/A | Mar 14, 2017 | $23.68M |
| Sep 30, 2016 | $13.50 | $12.30 | N/A | +9.76% | Beat | -7.2% | N/A | N/A | Oct 25, 2016 | $26.13M |
| Jun 30, 2016 | $8.25 | $9.75 | N/A | -15.38% | Miss | -44.4% | N/A | N/A | Jul 21, 2016 | $26.29M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.00, after -$56.71 the year before. It was $26.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.00 | N/A |
| Dec 31, 2024 | -$56.71 | N/A |
| Dec 31, 2023 | -$55.14 | N/A |
| Dec 31, 2022 | -$47.21 | -218.6% |
| Dec 31, 2021 | $39.79 | -61.1% |
| Dec 31, 2020 | $102.20 | +579.5% |
| Dec 31, 2019 | $15.04 | +31.1% |
| Dec 31, 2018 | $11.47 | -27.2% |
| Dec 31, 2017 | $15.76 | -40.1% |
| Dec 31, 2016 | $26.32 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 5,200 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q3 | Sep 30, 2024 | 5,219 | 5 | |
| 2024Q2 | Jun 30, 2024 | 5,060 | 6 |
2024Q3 Earnings Call
Opening remarks
Eric Ribner Investor Relations Thank you very much. Before we begin, please note that statements made during this presentation may be deemed forward-looking statements within the meaning of federal securities laws. These statements are subject to known and unknown risks and uncertainties that may cause actual events to differ from those expressed or implied in such statements. These risks include but are not limited to those set forth in the risk factor statements in the company's annual report on Form 20-F filed with the SEC. Trinity Biotech undertakes no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after today or the occurrence of unanticipated events. I will now hand the call over to John Gillard, President and CEO of Trinity Biotech, who will give an overview of Q2 performance and a business update. John will be followed by the company's Chief Financial Officer, Louise Tallon, who will give further details on third quarter financials. John, I'll turn it over to you.
John Gillard President and CEO Good morning, everyone and thank you for joining today’s call. It has been an exciting time for our company. I have a lot to share with you today. Our company has been significantly transformed over the past year and we are now looking into the future and growth drivers that will create meaningful value for our shareholders. On our call today, I want to focus on three key elements. One, planning for long-term growth, which we believe will be driven by our continuous glucose monitor or CGM for diabetes management. As we progress towards the commercial launch of our next-generation solution, we are incredibly excited about the opportunity our innovative and pioneering approach presents in this fast market, a market that is already worth over $10 billion a year and projected to grow rapidly. In addition, in order to provide shareholders with more opportunities for value accretion, we are building out our pipeline of high-growth potential products through the acquisition of innovative prostate cancer and preeclampsia test technology, plus a strategic investment in a sepsis diagnostic technology. Moving on to two, I will also update you on our continued strong execution of our comprehensive transformation plan, which is establishing the profitability infrastructure for our existing and future business lines. This will support R&D for growth and balance sheet strengthening, as well as increasing the value of many of our existing business lines. And finally, three, I will speak to how we have strengthened the company by successfully addressing NASDAQ listing deficiencies, removing an important overhang from our stock. Before I address each of those three areas, let me first speak to our Q3 performance.
Frequently Asked Questions About TRIB
When is Trinity Biotech's next earnings date?
Trinity Biotech's next earnings report is expected for Dec 22, 2026.
How often does TRIB beat earnings estimates?
Trinity Biotech beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of -39.50%.
TRIB pages: Overview, Earnings, Financials, Competitors